GlassScriptPhysician profile
Amy B Kewin
NPI 1821088972
$1,703.13
in general payments reported to CMS, 2019-2025
17 companies · $358 in 2025
The $358 reported for 2025 was more than what 88% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $15.95 · 2021: $52.46 · 2022: $121 · 2023: $317 · 2024: $728 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,402.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $498.71 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $314.63 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $184.25 | 2022-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $112.14 | 2025 | |
| Cranial Technologies, INC | $102.80 | 2019-2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $101.73 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $71.71 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $57.28 | 2021-2025 | Bexsero, Flulaval Quadrivalent |
| Merck Sharp & Dohme LLC | $50.33 | 2022-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $38.87 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.42 | 2019-2021 | |
| Tris Pharma INC | $33.98 | 2022-2025 | Onyda Xr |
| Astrazeneca Pharmaceuticals LP | $23.25 | 2023 | Flumist Quadrivalent |
| Genentech USA, INC. | $23.20 | 2019 | |
| Sobi, INC | $19.68 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $17.50 | 2019 | |
| Allegis Pharmaceuticals, LLC | $15.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Kewin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.